2023 Fiscal Year Final Research Report
Therapeutic effects of Vasohibin-2 peptide vaccine against chronic kidney diseases
| Project/Area Number |
21K08278
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53040:Nephrology-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 糖尿病性腎症 / Vasohibin-2 / ワクチン療法 / アンギオポイエチン2 / マクロファージ |
|---|
| Outline of Final Research Achievements |
In this study, we examined the preventive effects of vasohibin-2 (VASH2)-targeting peptide vaccine in diabetic nephropathy mouse model. Treatment with the VASH2-targeting peptide vaccine successfully induced serum anti-VASH2 antibody, and significantly prevented hyperglycemia-induced albuminuria and glomerular hypertrophy, independent of blood glucose levels. The vaccination significantly inhibited renal angiopoietin-2 (Angpt2) expression and prevented glomerular macrophage infiltration in diabetic mice. These results suggest that the VASH2-targeting peptide vaccine may be useful as a preventive strategy against diabetic nephropathy through inhibiting Angpt2-mediated glomerular microinflammation.
|
| Free Research Field |
腎臓内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、慢性腎臓病患者の中で透析療法を必要とする末期腎不全へ移行する可能性が最も高い糖尿病性腎症に対する新たな予防・治療法としてVasohibin-2 (VASH2)を標的としたペプチドワクチン接種の実行可能性を示唆するものである。ペプチドワクチンは抗体製剤よりも安価で利便性が高く、早期の臨床応用につながると考えられる。糖尿病性腎症が特に高齢者で増加しており、ポリファーマシーの回避などの点からもペプチドワクチン療法は有用な手段であり、既存の治療と組み合わせてVASH2ペプチドワクチンの接種が糖尿病性腎症の腎予後を改善させる可能性がある。
|
